Clinical trials: Neovascular Macular Degeneration
Neovascular Age-related Macular Degeneration
Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
The purpose of this study was to compare the efficacy of 0.5 mg ranibizumab versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability.
- Trial name
- SALT (NCT01958918)
- Testing
- Ranibizumab, Aflibercept
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 712 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD)
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
The purpose of this research study is to observe the patient's clinical care and how EYLEA® HD is used as a treatment in real-world settings.
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Visual Impairment
- Trial name
- SPECTRUM-US (NCT06398080)
- Testing
- aflibercept 8 mg
- Sponsor
- Regeneron Pharmaceuticals
Age-related Macular Degeneration (AMD)
Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
This was a retrospective cohort study to assess the treatment history, demographic characteristics, clinical characteristics, and early treatment patterns of patients who received brolucizumab for neovascular age-related macular…
- Trial name
- NCT05037396
- Testing
- Brolucizumab
- Where
- United States
- Volunteers
- 9,457 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Study of DS-7080a for the Treatment of Macular Degeneration
The purpose of this study is to test DS-7080a, a monoclonal antibody, as a new treatment for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME).
- Trial name
- NCT02530918
- Testing
- DS-7080a, Ranibizumab
- Where
- 12 sites in United States
- Volunteers
- 56 people
- Sponsor
- Daiichi Sankyo
Age Related Macular Degeneration
Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration
Angiogenesis plays a key role in the development of choroidal neovascularizations (CNV) in age-related macular degeneration. Vascular endothelial growth factor (VEGF) is the most important factor involved in this angiogenetic…
- Trial name
- MANTA (NCT00710229)
- Testing
- Ranibizumab, Bevacizumab
- Where
- Austria
- Volunteers
- 320 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Macular Degeneration
Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)
This pilot study will evaluate home vision testing using a mobile medical application in participants with diabetic macular edema (DME) or neovascular age-related macula degeneration (nAMD) who receive intravitreal ranibizumab…
- Trial name
- NCT02420132
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age Related Macular Degeneration
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
Neovascular age-related macular degeneration (nAMD) is characterized by the presence of choroidal neovascularization (CNV). Choroidal neovascularization consists of abnormal blood vessels originating from the choroid and can lead…
- Trial name
- OCTOPUS (NCT04239027)
- Testing
- RTH258/Brolucizumab
- Where
- 40 sites in France
- Volunteers
- 210 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration (nAMD)
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related…
- Trial name
- NCT06470373
- Testing
- RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection
- Where
- 7 sites in United States
- Volunteers
- 434 people
- Sponsor
- Rophibio, Inc.
Neovascular Age-related Macular Degeneration
Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD
To evaluate the safety and tolerability of suprachoroidally administered CLS-AX following intravitreal anti-VEGF therapy in subjects with neovascular age-related macular degeneration (AMD)
- Trial name
- OASIS (NCT04626128)
- Testing
- CLS-AX, Anti-VEGF
- Where
- 11 sites in United States
- Volunteers
- 27 people
- Sponsor
- Clearside Biomedical, Inc.
Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage.
- Trial name
- NCT06817343
- Testing
- Aflibercept (2.0 mg)
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Exegenesis Bio
Age-Related Macular Degeneration
Proton Radiation Therapy for Macular Degeneration
This is a pilot study to determine if proton radiation therapy can provide effective and safe treatment for subfoveal neovascularization membrane (SNVM).
- Trial name
- NCT01833325
- Testing
- Proton radiation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Florida
Neovascular Age Related Macular Degeneration(nAMD)
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- ASCEND (NCT07798375)
- Testing
- VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration
- Volunteers
- 244 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Age-Related Macular Degeneration
Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects with neovascular AMD. KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral…
- Trial name
- NCT05657301
- Testing
- KH631
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
Age-related Macular Degeneration
A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects
The study is to evaluate the efficacy and safety of Sanhuangjingshimingwan in Wet AMD.
- Trial name
- NCT04486963
- Testing
- Sanhuangjingshimingwan
- Where
- 6 sites in China
- Volunteers
- 78 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Supplemental Adjuvants for Intracellular Nutrition and Treatment
Nutritional supplements have an augmentative effect on the outcomes of standard treatment of diabetic macular edema (DME) and Neovascular Age-Related Macular Degeneration (NAMD).
- Trial name
- SAINTS (NCT00893724)
- Testing
- Neutral pills with no medicinal effect, Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals, Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mid-Atlantic Retina Consultations, Inc.
Neovascular Age-Related Macular Degeneration
ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of multiple doses of ARC1905 intravitreous injection when administered in combination with multiple doses of Lucentis® 0.5 mg/eye…
- Trial name
- NCT00709527
- Testing
- Avacincaptad Pegol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ophthotech Corporation
Acute Macular Degeneration
The Accuracy of Home Monitoring for Acute Macular Degeneration (AMD) Disease Activity
Currently the best treatment for "wet" macular degeneration involves regular injections of Ranibizumab (Lucentis). In the initial clinical trials, the drug was injected into the eye every month.
- Trial name
- NCT02304068
- Testing
- Home monitoring, Hospital assessment
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Trial name
- TORRONTES (NCT07496567)
- Testing
- Tiespectus, Aflibercept
- Where
- 71 sites in United States, Brazil and 7 more
- Volunteers
- 960 people
- Sponsor
- EyeBiotech Ltd.